Chester County News and Community Website
Aclaris Therapeutics, Inc. (NASDAQ: ACRS), headquartered in Wayne, PA, is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit www.aclaristx.com.
WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has granted stock options and restricted stock units (RSUs) to multiple new employees, including its recently appointed President and Chief Operating Officer, …
Aclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement Plan Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has entered into an exclusive licensing agreement with Biosion, Inc., securing worldwide rights, excluding Greater China, to two promising antibody therapies. This …
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced its financial results for the third quarter of 2024, alongside significant corporate updates. The company marked a pivotal milestone with …
Aclaris Therapeutics Highlights Key Advances and Financial Results for Q3 2024 Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) has commenced its Phase 2a clinical trial for ATI-2138, an innovative oral covalent inhibitor targeting ITK and JAK3, aimed at treating moderate to …
Aclaris Therapeutics Launches Phase 2a Trial for ATI-2138 in Atopic Dermatitis Read More WAYNE, PA — Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced its financial results for the second quarter of 2024 and provided a corporate update. The company reported net revenue of $2.8 …
Aclaris Therapeutics Reports Q2 2024 Financial Results and Updates Read More